Published in N Engl J Med on July 03, 1997
Treatment With Tamoxifen in Cryptococcal Meningitis | NCT03112031
Combination antifungal therapy for cryptococcal meningitis. N Engl J Med (2013) 4.87
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med (2016) 3.59
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun (2005) 3.13
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86
Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med (2007) 2.85
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis (2010) 2.31
Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J (2001) 1.83
Covariate adjustment in randomized trials with binary outcomes: targeted maximum likelihood estimation. Stat Med (2009) 1.70
The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis (2014) 1.68
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother (1999) 1.63
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis (2009) 1.60
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med (2012) 1.53
Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun (2007) 1.52
HTLV-1 and HIV infections of the central nervous system in tropical areas. J Neurol Neurosurg Psychiatry (2000) 1.51
Cryptococcal meningitis: epidemiology and therapeutic options. Clin Epidemiol (2014) 1.49
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One (2008) 1.43
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis (2006) 1.43
Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clin Infect Dis (2016) 1.40
A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis (2010) 1.39
Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob Agents Chemother (2001) 1.37
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun (2001) 1.32
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
An update on Cryptococcus among HIV-infected patients. Int J STD AIDS (2010) 1.26
Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status. PLoS One (2013) 1.23
Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis (2016) 1.22
Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis (2008) 1.20
A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS (2012) 1.19
Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother (1998) 1.19
Treatment of cryptococcal meningitis in resource limited settings. Curr Opin Infect Dis (2009) 1.18
Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun (2007) 1.17
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother (2013) 1.16
Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One (2012) 1.16
Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J (2010) 1.16
Evaluation and treatment of chronic meningitis. Neurohospitalist (2014) 1.13
Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother (2006) 1.13
Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother (2006) 1.13
Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother (2004) 1.10
Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother (2010) 1.09
Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics (2011) 1.06
Therapy of Cryptococcal Meningitis in non-HIV-infected Patients. Curr Infect Dis Rep (2001) 1.05
Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994. J Clin Microbiol (1998) 1.04
Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania. J Int AIDS Soc (2014) 1.04
Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis. Open Forum Infect Dis (2015) 1.03
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (2006) 1.03
Clinical presentation, diagnosis and management of Cryptococcus gattii cases: Lessons learned from British Columbia. Can J Infect Dis Med Microbiol (2009) 1.03
Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol (2014) 1.02
Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis (2004) 1.02
In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother (2003) 1.01
Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol (2011) 0.98
New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS (2013) 0.98
Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother (2013) 0.96
SREB, a GATA transcription factor that directs disparate fates in Blastomyces dermatitidis including morphogenesis and siderophore biosynthesis. PLoS Pathog (2010) 0.94
Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens. Bioorg Med Chem (2010) 0.92
Recent advances in management of cryptococcal meningitis: commentary. F1000 Med Rep (2010) 0.91
Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in benin city, Nigeria. Oman Med J (2012) 0.90
Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol (2014) 0.90
A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. Proteomics (2009) 0.89
Importance of follow-up cerebrospinal fluid analysis in cryptococcal meningoencephalitis. Dis Markers (2014) 0.89
Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa. PLoS One (2010) 0.89
In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother (2006) 0.88
A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J Antimicrob Chemother (2003) 0.88
Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal. HIV AIDS (Auckl) (2011) 0.87
Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. Curr Trop Med Rep (2015) 0.87
Massive cerebral edema resulting in brain death as a complication of Cryptococcus neoformans meningitis. J Community Hosp Intern Med Perspect (2015) 0.87
The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. J Infect (2012) 0.86
Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models. Front Microbiol (2012) 0.86
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. Antimicrob Agents Chemother (2013) 0.86
A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLoS One (2014) 0.85
Differential gene expression in auristatin PHE-treated Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 0.85
Cryptococcal Meningitis in HIV-Infected Patients. Curr Infect Dis Rep (2000) 0.85
Management of cryptococcosis: how are we doing? PLoS Med (2007) 0.84
Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. Future Virol (2013) 0.84
Cryptococcal meningitis in patients with or without human immunodeficiency virus: experience in a tertiary hospital. Yonsei Med J (2011) 0.84
Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest. PLoS One (2014) 0.84
Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome. Antimicrob Agents Chemother (2011) 0.84
Management of cryptococcal meningitis in HIV-infected patients: Experience from western India. Indian J Sex Transm Dis (2010) 0.82
The role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high temperature growth and virulence. Fungal Genet Biol (2014) 0.81
Effect of auristatin PHE on microtubule integrity and nuclear localization in Cryptococcus neoformans. Antimicrob Agents Chemother (2002) 0.81
Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrob Agents Chemother (2015) 0.81
Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgrad Med J (2012) 0.80
Asymptomatic cryptococcemia in resource-limited settings. Curr HIV/AIDS Rep (2013) 0.80
Combinatorial strategies for combating invasive fungal infections. Virulence (2016) 0.80
Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages. Antimicrob Agents Chemother (2000) 0.80
Persistent Cryptococcal Brain Infection despite Prolonged Immunorecovery in an HIV-Positive Patient. Case Rep Neurol Med (2014) 0.79
Outcome Assessments in Clinical Trials of Cryptococcal Meningitis: Considerations on Use of Early Fungicidal Activity as a Potential Surrogate Endpoint for All-Cause Mortality. Curr Treat Options Infect Dis (2014) 0.79
Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome. Front Microbiol (2016) 0.79
Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. Antimicrob Agents Chemother (2009) 0.79
Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan. J Venom Anim Toxins Incl Trop Dis (2015) 0.79
Comparative pharmacokinetics of continuous and conventional intrathecal amphotericin B in rabbits. Antimicrob Agents Chemother (2012) 0.78
A fatal case of AIDS-defining meningoencephalitis by C. neoformans, sensitive to antifungal therapy. Eur J Med Res (2010) 0.78
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med (1991) 7.01
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature (1994) 5.68
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother (1988) 4.79
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.25
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis (2001) 4.01
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med (1983) 3.97
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Oral azole drugs as systemic antifungal therapy. N Engl J Med (1994) 3.96
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med (1992) 3.65
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58
Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science (1988) 3.44
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Prosthetic valve endocarditis. Analysis of 38 cases. Circulation (1973) 3.29
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Inactivation of Norwalk virus in drinking water by chlorine. Appl Environ Microbiol (1985) 3.12
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
A conserved Streptococcus pyogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin. Microb Pathog (1993) 2.99
A newly recognized cause of travelers' diarrhea: enteroadherent Escherichia coli. J Infect Dis (1985) 2.94
Treatment of infective endocarditis: a 10-year comparative analysis. Circulation (1978) 2.90
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Cell-mediated immunity in Cryptococcosis. Cell Immunol (1974) 2.68
Serious infections from Bacillus sp. JAMA (1979) 2.67
Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med (1988) 2.65
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med (1994) 2.60
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
The isolation and characterization of a Norwalk virus-specific cDNA. J Clin Invest (1991) 2.42
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Intern Med (1990) 2.35
Pathogenicity of enteroadherent Escherichia coli in adult volunteers. J Infect Dis (1986) 2.32
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis (1981) 2.27
In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother (1978) 2.21
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Teichoic acid serologic diagnosis of staphylococcal endocarditis. Use of gel diffusion and counterimmunoelectrophoretic methods. Ann Intern Med (1975) 2.15
Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med (1982) 2.14
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J Clin Microbiol (1991) 2.12
Microbiologic study of street heroin and injection paraphernalia. J Infect Dis (1974) 2.10
Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis (2007) 2.09
Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother (1993) 2.09
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
Genomic fingerprinting of Bartonella species by repetitive element PCR for distinguishing species and isolates. J Clin Microbiol (1995) 2.09
Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J Clin Microbiol (1996) 2.08
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol (1996) 2.07
Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis (1990) 2.06
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med (1987) 2.05
Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann Intern Med (1987) 2.05
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am Rev Respir Dis (1984) 2.03
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci. JAMA (1989) 2.03
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Facial neuromuscular retraining for oral synkinesis. Plast Reconstr Surg (1997) 1.97
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med (1999) 1.96
Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. II. Postmortem pathological correlations. Stroke (1987) 1.96
The MRI appearance of cavernous malformations (angiomas). J Neurosurg (1987) 1.93